Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial

Kazumoto Iijima, Mayumi Sako, Kandai Nozu et al. · The Lancet · 2014 · 443 citations

Medicine, Nephrology, Pediatrics +14

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Ronald van Vollenhoven, Paul Emery, Clifton O. Bingham et al. · Annals of the Rheumatic Diseases · 2012 · 391 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia

Sara Barmettler, Mei‐Sing Ong, Jocelyn R. Farmer et al. · JAMA Network Open · 2018 · 342 citations · Full text

Life Sciences, Hematology, Immunology +16

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysis

Edward Keystone, Roy Fleischmann, Paul Emery et al. · Arthritis & Rheumatism · 2007 · 334 citations

Medicine, Internal Medicine, Pharmacotherapy +15